Skip to Content

Generic Cleocin T Availability

See also: Generic Cleocin Vaginal

Cleocin T is a brand name of clindamycin topical, approved by the FDA in the following formulation(s):

CLEOCIN T (clindamycin phosphate - gel;topical)

  • Manufacturer: PHARMACIA AND UPJOHN
    Approval date: January 7, 1987
    Strength(s): EQ 1% BASE [RLD] [AB]

CLEOCIN T (clindamycin phosphate - lotion;topical)

  • Manufacturer: PHARMACIA AND UPJOHN
    Approval date: May 31, 1989
    Strength(s): EQ 1% BASE [RLD] [AB]

CLEOCIN T (clindamycin phosphate - solution;topical)

  • Manufacturer: PHARMACIA AND UPJOHN
    Approved Prior to Jan 1, 1982
    Strength(s): EQ 1% BASE [RLD] [AT]

Has a generic version of Cleocin T been approved?

Yes. The following products are equivalent to Cleocin T:

CLINDA-DERM (clindamycin phosphate solution;topical)

  • Manufacturer: PADDOCK LLC
    Approval date: September 30, 1992
    Strength(s): EQ 1% BASE [AT]

clindamycin phosphate gel;topical

  • Manufacturer: FOUGERA PHARMS
    Approval date: January 28, 2000
    Strength(s): EQ 1% BASE [AB]

clindamycin phosphate lotion;topical

  • Manufacturer: FOUGERA PHARMS
    Approval date: January 31, 2002
    Strength(s): EQ 1% BASE [AB]

clindamycin phosphate solution;topical

  • Manufacturer: FOUGERA PHARMS
    Approval date: February 14, 2006
    Strength(s): EQ 1% BASE [AT]
  • Manufacturer: FOUGERA PHARMS INC
    Approval date: June 5, 1997
    Strength(s): EQ 1% BASE [AT]
  • Manufacturer: G AND W LABS INC
    Approval date: September 1, 1988
    Strength(s): EQ 1% BASE [AT]
  • Manufacturer: GLASSHOUSE PHARMS
    Approval date: February 8, 2018
    Strength(s): EQ 1% BASE [AT]
  • Manufacturer: PERRIGO NEW YORK
    Approval date: November 30, 1995
    Strength(s): EQ 1% BASE [AT]
  • Manufacturer: TARO PHARM INDS
    Approval date: March 31, 2004
    Strength(s): EQ 1% BASE [AT]
  • Manufacturer: TELIGENT PHARMA INC
    Approval date: December 30, 2016
    Strength(s): EQ 1% BASE [AT]
  • Manufacturer: VINTAGE PHARMS
    Approval date: May 29, 2015
    Strength(s): EQ 1% BASE [AT]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cleocin T. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
ATTopical products. There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays and suppositories. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of in vivo bioequivalence has been granted and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded AT. Pharmaceutically equivalent topical products that raise questions of bioequivalence, including all post-1962 non-solution topical drug products, are coded AB when supported by adequate bioequivalence data, and BT in the absence of such data.